Baseline characteristics of patients
bone-only disease, TNBC
BRAIN METASTASIS, METASTASIS, LUNG METASTASIS, SOFT TISSUE METASTASIS, BONE METASTASIS, ONCOLOGY, LIVER METASTASIS
From September 2018 to September 2021, 40 patients with advanced TNBC were included in this study. The median age was 56, with an age range of 27 to 76. Three patients (7.5%) had an ECOG PS score of 0, while 37 (92.5%) had an ECOG PS score of 1. The median number of metastatic sites of all patients was 2 (0–5). Nine (22.5%), nine (22.5%) and thirteen (32.5%) developed lung metastasis, liver metastasis and bone metastasis, respectively. There was no patient had bone-only disease. All patients received previous chemotherapy in the advanced setting, with the median previous lines of 2 (1–5). A total of 24, 32 and 20 patients received prior taxane therapy, anthracycline therapy and platinum therapy, respectively (Table 
Baseline characteristics of patients* Including 13 patients with bone metastasis, one with brain metastasis, two with skin or soft tissue metastasis, 16 with chest wall metastasis, and two with adrenal metastasis# Including 15 patients given capecitabine, 13 given cyclophosphamide, ten given gemcitabine, nine given vinorelbine, one given fluorouracil, one given eribulin, one given utidelone and one given raltitrexedECOG PS: Eastern Cooperative Oncology Group performance status